BIRC5 and non-small cell lung carcinoma: Survivin is expressed in at least 80% of tumor patients with NSCLC, and the suppression of surviving expression abrogates survivin-mediated apoptosis, which results in increased in tumor-cell death and eventually sensitivity to anticancer therapy [24].